Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||ORY-1001||Phase I||Actionable||In a Phase I trial, ORY-1001 (iadademstat) treatment demonstrated safety in patients with acute myeloid leukemia and resulted in complete remission in one patient and hematologic improvement in 2 additional patients of 27 patients in the dose escalation phase, and resulted in decreased blast percentage and induction of differentiation in patients in the expansion cohort (PMID: 33052756).||33052756|
|Unknown unknown||acute myeloid leukemia||not applicable||ORY-1001||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ORY-1001 decreased colony forming ability in several acute myeloid leukemia (AML) cell lines and primary AML samples in culture, and reduced tumor growth in AML cell line xenograft model (PMID: 29502954).||29502954|
|PubMed Id||Reference Title||Details|
|(29502954)||ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.||Full reference...|
|(33052756)||First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.||Full reference...|